#AANAM – Reldesemtiv Reduces Lung Function Decline and ALS Progression, Phase 2 Trial Shows
Reldesemtiv (formerly known as CK-2127107) reduces lung function decline and overall disease progression, without significant adverse events, in people with amyotrophic lateral sclerosis (ALS), a Phase 2 trial shows. The study, however, did not meet its primary endpoint. The new findings from the…